| For: | Leowattana W, Leowattana T, Leowattana P. Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer. World J Gastrointest Oncol 2023; 15(6): 959-972 [PMID: 37389105 DOI: 10.4251/wjgo.v15.i6.959] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i6/959.htm |
| Number | Citing Articles |
| 1 |
Atsuto Katano. Stereotactic body radiotherapy for inoperable primary and recurrent cholangiocarcinoma: A single-institution retrospective analysis. Tzu Chi Medical Journal 2026; 38(2) doi: 10.4103/tcmj.TCMJ-D-25-00067
|
| 2 |
Tamanna Sharma, Anuj Kumar Tomer, R. Mankamna Kumari, Surendra Nimesh. Cancer Therapy. 2024; doi: 10.1016/B978-0-443-15401-0.00004-X
|
| 3 |
Ying Yue, Yingying Wang, Jingjing Feng, Min Yao, Yuanzhen Suo. Tumor treating fields suppress tumor cell growth and induce immunogenic cell death biomarkers in biliary tract cancer cell lines. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-16341-6
|
| 4 |
Zhenggang Ren, Tingbo Liang, Shanzhi Gu, Hongfeng Gou, Chuang Peng, Yueyin Pan, Tianqiang Song, Haichuan Su, Ke Cao, Houjie Liang, Jieer Ying, Zhimin Geng, Wenchang Yu, Haitao Zhao, Yuxian Bai, Chunyi Hao, Yimin Mao, Wei Li, Lu Wang, Dongliang Li, Wenmiao Wang, Nan Li, Usha Malhotra, Shukui Qin. First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study. Advances in Therapy 2026; doi: 10.1007/s12325-026-03578-4
|